Try our mobile app

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

Published: 2020-06-29 11:15:00 ET
<<<  go to KNSA company page
  • Primary and all major secondary efficacy endpoints were highly statistically significant 
  • Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p